EMN26 study on Iberdomide reported substantial response improvements in over 50% of Multiple Myeloma treated patients

EMN26 study | Iberdomide (IBER) is a novel, potent, oral cereblon (CRBN) E3 ligase modulator (CELMoD™) with greater tumoricidal and immune-modulatory effects compared with IMiDs

EMN26 study on Iberdomide reported substantial response improvements in over 50% of Multiple Myeloma treated patients

2024-02-19 // 0 Comments

Rotterdam, The Netherlands, 2024-Feb-19 — /EPR Network/ — The European Myeloma Network (EMN) conducted a phase 2 study with Iberdomide as maintenance therapy after autologous [read full press release…]

Daratumumab Market Precise Analysis and Forecast Assumptions during 2019-2025

2019-06-10 // 0 Comments

ALBANY, US, 2019-Jun-10 — /EPR Network/ — Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it [read full press release…]